Last reviewed · How we verify
Luveris® 25 IU
Luveris® 25 IU is a Small molecule drug developed by EMD Serono. It is currently FDA-approved. Also known as: Lutropin alfa, Recombinant human luteinizing hormone (r-hLH).
Luveris 25 IU is a medication used to treat Hypogonadotropic Hypogonadism and Infertility in women. It is a form of Lutropin Alfa for Injection, which stimulates the production of luteinizing hormone (LH) in the body.
At a glance
| Generic name | Luveris® 25 IU |
|---|---|
| Also known as | Lutropin alfa, Recombinant human luteinizing hormone (r-hLH) |
| Sponsor | EMD Serono |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment (PHASE4)
- Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L]) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Luveris® 25 IU CI brief — competitive landscape report
- Luveris® 25 IU updates RSS · CI watch RSS
- EMD Serono portfolio CI
Frequently asked questions about Luveris® 25 IU
What is Luveris® 25 IU?
Who makes Luveris® 25 IU?
Is Luveris® 25 IU also known as anything else?
What development phase is Luveris® 25 IU in?
Related
- Manufacturer: EMD Serono — full pipeline
- Also known as: Lutropin alfa, Recombinant human luteinizing hormone (r-hLH)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing